Latest Everolimus Stories

2012-05-03 15:11:39

Presentations at the 4th IMPAKT Breast Cancer Conference A new analysis may help doctors identify breast cancer patients who will benefit from treatment with the immune suppressant drug everolimus, say French researchers at the 4th IMPAKT Breast Cancer Conference in Brussels, Belgium. Everolimus is currently used as an immunosuppressant to prevent patients rejecting transplanted organs and in the treatment of renal cell cancer. Research is also being conducted into the drug's use in...

2012-05-02 15:07:00

IDIBELL researchers discover that combining two mTOR inhibitors cause the regression of hepatocellular carcinoma The combination of two inhibitors of protein mTOR stops the growth of primary liver cancer and destroys tumor cells, according to a study by researchers of the Group of Metabolism and Cancer at Bellvitge Biomedical Research Institute (IDIBELL). The study results are been published on the online edition of the journal Science Translational Medicine. Primary liver cancer or...

2012-04-02 15:53:36

Aberrations in translation regulators associated with hormone receptor-positive disease survival Four proteins involved in translation, the final step of general protein production, are associated with poor prognosis in hormone-receptor-positive breast cancer when they are dysregulated, researchers reported at the AACR Annual Meeting 2012. All of the aberrantly activated translational proteins are regulated by the PI3K/mTOR molecular signaling pathway, which has been implicated in...

Word of the Day
  • A bookseller; now, especially, a dealer in rare and curious books.
This word comes from a Greek phrase meaning 'book seller.'